AlphaQuest LLC Acquires 147,537 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

AlphaQuest LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,462.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 157,623 shares of the company's stock after purchasing an additional 147,537 shares during the period. AlphaQuest LLC owned about 0.05% of Amneal Pharmaceuticals worth $1,248,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of AMRX. JPMorgan Chase & Co. boosted its holdings in Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after purchasing an additional 378,136 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Amneal Pharmaceuticals during the fourth quarter worth about $2,946,000. Polar Asset Management Partners Inc. grew its position in Amneal Pharmaceuticals by 122.5% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock worth $3,270,000 after purchasing an additional 216,400 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Amneal Pharmaceuticals by 16.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock valued at $11,689,000 after buying an additional 202,863 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AMRX. Barclays boosted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $10.80.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX traded down $0.09 on Thursday, hitting $8.79. 1,931,253 shares of the stock traded hands, compared to its average volume of 1,442,528. The business's fifty day moving average is $8.26 and its two-hundred day moving average is $8.36. Amneal Pharmaceuticals, Inc. has a 12 month low of $5.18 and a 12 month high of $9.48. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -12.93 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same quarter in the previous year, the company posted $0.14 EPS. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the transaction, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 240,000 shares of company stock valued at $2,004,000 in the last 90 days. 26.56% of the stock is currently owned by company insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.